Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 1 min

Next-Generation Psychedelic Drug Development

AI Summary
  • Psychedelic medicine shows rapid clinical promise for depression, anxiety and post-traumatic stress disorder.
  • Emerging analogues and treatment regimens introduce many variables requiring rigorous testing and standardised study designs.
  • Review assesses assay and model strengths and limitations and provides practical guidance for next generation drug development.
Summarise with AI (MRCPsych/FRANZCP)

ACS Chem Neurosci. 2026 Nov 4;17(21):3462-3477. doi: 10.1021/acschemneuro.6c00492.

ABSTRACT

Psychedelic medicine has gained rapid popularity for the treatment of a variety of neuropsychiatric disorders, including depression, anxiety, and post-traumatic stress disorder. As novel psychedelic analogues and treatment regimes emerge, increasing numbers of variables are being tested. Here, we review various approaches and considerations for novel psychedelic therapies, including the strengths and limitations of current assays and models. Finally, we provide guidance and considerations for next-generation psychedelic drug development.

PMID:42980080 | DOI:10.1021/acschemneuro.6c00492

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

⭐ My Revision List

close chatgpt icon
ChatGPT

Enter your request.

← →
RAISR4D CME/CPD Evidence Nodes
Swipe to navigate RAISR4D CME/CPD evidence nodes.
CME/CPD